Alteration of TGF-β-mediated Signaling Pathways during Adriamycin(ADM) Resistant in NCI-H23 Non-small Cell Lung Cancer(NSCLC)
碩士 === 臺北醫學大學 === 醫學研究所 === 91 === Chemotherapy is a common therapy used for controlling metastatic tumor growth on cancer treatment today. However, it also often causes tumor cells resistant to the treatment. The displaying drug-resistance has been reported to be strongly associated with tumorgenes...
Main Authors: | Bing-Ying Ho, 何秉穎 |
---|---|
Other Authors: | Neng-Yao Shih |
Format: | Others |
Language: | zh-TW |
Published: |
2003
|
Online Access: | http://ndltd.ncl.edu.tw/handle/08868561853374927826 |
Similar Items
-
Synergistic Effect of Baicalin and Adriamycin in Resistant HL-60/ADM Leukaemia Cells
by: Jing Zheng, et al.
Published: (2017-08-01) -
Pilose Antler Peptide-3.2KD Ameliorates Adriamycin-Induced Myocardial Injury Through TGF-β/SMAD Signaling Pathway
by: Yan Xu, et al.
Published: (2021-05-01) -
Small extracellular vesicles deliver TGF‐β1 and promote adriamycin resistance in breast cancer cells
by: Chunli Tan, et al.
Published: (2021-05-01) -
Lung microbiome alterations in NSCLC patients
by: Leliang Zheng, et al.
Published: (2021-06-01) -
A microRNA signature of response to erlotinib is descriptive of TGFβ behaviour in NSCLC
by: Madeline Krentz Gober, et al.
Published: (2017-06-01)